NEW YORK (TheStreet) -- Shares of Endo (ENDP) - Get Report were up 13.13% to $22.92 in mid-morning trading on Friday after the pharmaceutical company's board named Paul Campanelli CEO, effective immediately.
Campanelli succeeds Rajiv De Silva, who has stepped down as CEO and board member nearly a year after Endo completed its acquisition of Par Pharmaceutical.
Campanelli was CEO of Par Pharmaceutical before joining Endo after the 2015 acquisition as president of Endo's generic and over-the-counter drug business.
"Given the continued evolution of Endo's business and Paul's impressive track record of delivering strong operating results, the board concluded that Paul is the right leader for Endo at this juncture as we focus on execution and increasing the value of our attractive U.S. branded, U.S. generic and international pharmaceutical assets," Roger Kimmel, chairman of Endo's board, said in a statement.
Separately, TheStreet Ratings team rates the stock as a "sell" with a ratings score of D.
Endo's weaknesses include its disappointing return on equity, generally disappointing historical performance in the stock itself and generally high debt management risk.
You can view the full analysis from the report here: ENDP
TheStreet Ratings objectively rated this stock according to its "risk-adjusted" total return prospect over a 12-month investment horizon. Not based on the news in any given day, the rating may differ from Jim Cramer's view or that of this article's author.